KR101404893B1 - 트랜스-4-［［(5ｓ)-5-［［［3,5-비스(트리플루오로메틸)페닐］메틸］ (2-메틸-2ｈ-테트라졸-5-일)아미노］-2,3,4,5-테트라히드로-7,9-디메틸-1ｈ-1-벤즈아제핀-1-일］메틸］-시클로헥산카르복실산 - Google Patents

트랜스-4-［［(5ｓ)-5-［［［3,5-비스(트리플루오로메틸)페닐］메틸］ (2-메틸-2ｈ-테트라졸-5-일)아미노］-2,3,4,5-테트라히드로-7,9-디메틸-1ｈ-1-벤즈아제핀-1-일］메틸］-시클로헥산카르복실산 Download PDF

Info

Publication number
KR101404893B1
KR101404893B1 KR1020117031449A KR20117031449A KR101404893B1 KR 101404893 B1 KR101404893 B1 KR 101404893B1 KR 1020117031449 A KR1020117031449 A KR 1020117031449A KR 20117031449 A KR20117031449 A KR 20117031449A KR 101404893 B1 KR101404893 B1 KR 101404893B1
Authority
KR
South Korea
Prior art keywords
methyl
dimethyl
tetrahydro
amino
tetrazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020117031449A
Other languages
English (en)
Korean (ko)
Other versions
KR20120027426A (ko
Inventor
신차오 첸
스코트 알란 프랭크
데이비드 마이클 레믹
스티븐 웨인 페더슨
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42352717&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101404893(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20120027426A publication Critical patent/KR20120027426A/ko
Application granted granted Critical
Publication of KR101404893B1 publication Critical patent/KR101404893B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020117031449A 2009-06-30 2010-06-28 트랜스-4-［［(5ｓ)-5-［［［3,5-비스(트리플루오로메틸)페닐］메틸］ (2-메틸-2ｈ-테트라졸-5-일)아미노］-2,3,4,5-테트라히드로-7,9-디메틸-1ｈ-1-벤즈아제핀-1-일］메틸］-시클로헥산카르복실산 Expired - Fee Related KR101404893B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22170809P 2009-06-30 2009-06-30
US61/221,708 2009-06-30
PCT/US2010/040125 WO2011002696A1 (en) 2009-06-30 2010-06-28 Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid

Publications (2)

Publication Number Publication Date
KR20120027426A KR20120027426A (ko) 2012-03-21
KR101404893B1 true KR101404893B1 (ko) 2014-06-20

Family

ID=42352717

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117031449A Expired - Fee Related KR101404893B1 (ko) 2009-06-30 2010-06-28 트랜스-4-［［(5ｓ)-5-［［［3,5-비스(트리플루오로메틸)페닐］메틸］ (2-메틸-2ｈ-테트라졸-5-일)아미노］-2,3,4,5-테트라히드로-7,9-디메틸-1ｈ-1-벤즈아제핀-1-일］메틸］-시클로헥산카르복실산

Country Status (37)

Country Link
US (2) US8329688B2 (https=)
EP (1) EP2448933B1 (https=)
JP (1) JP5689875B2 (https=)
KR (1) KR101404893B1 (https=)
CN (1) CN102639528B (https=)
AR (1) AR077208A1 (https=)
AU (1) AU2010266537B2 (https=)
BR (1) BRPI1011931A2 (https=)
CA (1) CA2764425C (https=)
CL (1) CL2011003263A1 (https=)
CO (1) CO6480934A2 (https=)
CR (1) CR20110669A (https=)
DK (1) DK2448933T3 (https=)
DO (1) DOP2011000405A (https=)
EA (1) EA020600B1 (https=)
EC (1) ECSP11011551A (https=)
ES (1) ES2435293T3 (https=)
GT (1) GT201100321A (https=)
HR (1) HRP20130950T1 (https=)
IL (1) IL216655A (https=)
JO (1) JO2867B1 (https=)
MA (1) MA33385B1 (https=)
ME (1) ME01606B (https=)
MX (1) MX2011014024A (https=)
MY (1) MY157121A (https=)
NZ (1) NZ596820A (https=)
PE (1) PE20120538A1 (https=)
PL (1) PL2448933T3 (https=)
PT (1) PT2448933E (https=)
RS (1) RS52988B (https=)
SG (1) SG177413A1 (https=)
SI (1) SI2448933T1 (https=)
TN (1) TN2011000638A1 (https=)
TW (1) TWI450896B (https=)
UA (1) UA109409C2 (https=)
WO (1) WO2011002696A1 (https=)
ZA (1) ZA201108707B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005267436A1 (en) * 2004-06-24 2006-02-02 Eli Lilly And Company Compounds and methods for treating dyslipidemia
AR077208A1 (es) * 2009-06-30 2011-08-10 Lilly Co Eli Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam
ES2683350T3 (es) * 2011-07-08 2018-09-26 Novartis Ag Método para tratar la aterosclerosis en sujetos con alto nivel de triglicéridos
WO2014012401A1 (zh) * 2012-07-16 2014-01-23 上海恒瑞医药有限公司 苯并七元杂环类衍生物、其制备方法及其在医药上的应用
WO2014119947A1 (en) 2013-01-31 2014-08-07 Chong Kun Dang Pharmaceutical Corp. Biaryl- or heterocyclic biaryl-substituted cyclohexene derivative compounds as cetp inhibitors
CN105017085B (zh) * 2014-04-28 2018-06-29 中国科学院上海药物研究所 一类kcnq钾通道激动剂、其制备方法和用途
RU2703192C2 (ru) 2014-07-30 2019-10-15 Ф. Хоффманн-Ля Рош Аг Генетические маркеры для прогнозирования ответа на терапию поднимающими уровень hdl или имитирующими hdl агентами
TWI691331B (zh) 2014-09-26 2020-04-21 日商興和股份有限公司 脂質異常症治療劑
CN108456213B (zh) * 2017-02-22 2021-01-15 浙江九洲药业股份有限公司 一种3-氟-4-羟基环己烷羧酸酯的制备方法
WO2025093129A1 (en) 2023-11-01 2025-05-08 Newamsterdam Pharma B.V. Treatment and prevention of age-related macular degeneration using a cetp inhibitor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006002342A1 (en) 2004-06-24 2006-01-05 Eli Lilly And Company Compounds and methods for treating dyslipidemia

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4948639B1 (https=) 1970-12-15 1974-12-23
US6197786B1 (en) 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
CO5271716A1 (es) 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
ATE316957T1 (de) 2001-04-30 2006-02-15 Pfizer Prod Inc Verbindungen verwendbar als zwischenprodukte für 4-aminochinolinderivate
BR0306208A (pt) 2002-08-30 2004-10-13 Japan Tobacco Inc Compostos de dibenzilamina e seu uso farmacêutico
AU2003277285B2 (en) * 2002-10-04 2007-12-13 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
JP2006523218A (ja) 2003-03-04 2006-10-12 高砂香料工業株式会社 光学活性アミン類の製造方法
US20040204450A1 (en) 2003-03-28 2004-10-14 Pfizer Inc Quinoline and quinoxaline compounds
WO2005037796A1 (en) 2003-10-08 2005-04-28 Eli Lilly And Company Compounds and methods for treating dyslipidemia
WO2005097805A1 (en) 2004-03-26 2005-10-20 Eli Lilly And Company Compounds and methods for treating dyslipidemia
CN1972927A (zh) * 2004-06-24 2007-05-30 伊莱利利公司 用于治疗血脂障碍的化合物和方法
WO2006069162A1 (en) 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
AR077208A1 (es) * 2009-06-30 2011-08-10 Lilly Co Eli Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006002342A1 (en) 2004-06-24 2006-01-05 Eli Lilly And Company Compounds and methods for treating dyslipidemia

Also Published As

Publication number Publication date
MX2011014024A (es) 2012-04-20
IL216655A0 (en) 2012-02-29
CN102639528B (zh) 2014-07-16
DK2448933T3 (da) 2013-10-07
WO2011002696A1 (en) 2011-01-06
JP2012532106A (ja) 2012-12-13
EA201270099A1 (ru) 2012-05-30
DOP2011000405A (es) 2012-01-15
IL216655A (en) 2015-02-26
SG177413A1 (en) 2012-02-28
SI2448933T1 (sl) 2013-11-29
TW201113275A (en) 2011-04-16
ME01606B (me) 2014-09-20
RS52988B (sr) 2014-02-28
EP2448933A1 (en) 2012-05-09
US20100331309A1 (en) 2010-12-30
ES2435293T3 (es) 2013-12-18
UA109409C2 (ru) 2015-08-25
ZA201108707B (en) 2013-05-29
CO6480934A2 (es) 2012-07-16
US8329688B2 (en) 2012-12-11
US8299060B2 (en) 2012-10-30
AU2010266537B2 (en) 2013-04-18
CA2764425A1 (en) 2011-01-06
NZ596820A (en) 2013-07-26
CA2764425C (en) 2015-01-06
EP2448933B1 (en) 2013-08-28
JO2867B1 (en) 2015-03-15
EA020600B1 (ru) 2014-12-30
PT2448933E (pt) 2013-10-29
ECSP11011551A (es) 2012-01-31
HRP20130950T1 (hr) 2013-11-22
KR20120027426A (ko) 2012-03-21
CL2011003263A1 (es) 2012-07-27
MA33385B1 (fr) 2012-06-01
AR077208A1 (es) 2011-08-10
PE20120538A1 (es) 2012-05-09
AU2010266537A1 (en) 2012-02-02
TWI450896B (zh) 2014-09-01
TN2011000638A1 (en) 2013-05-24
MY157121A (en) 2016-05-13
BRPI1011931A2 (pt) 2016-04-19
PL2448933T3 (pl) 2014-01-31
US20120058990A1 (en) 2012-03-08
JP5689875B2 (ja) 2015-03-25
CN102639528A (zh) 2012-08-15
GT201100321A (es) 2012-11-15
CR20110669A (es) 2012-03-16

Similar Documents

Publication Publication Date Title
KR101404893B1 (ko) 트랜스-4-［［(5ｓ)-5-［［［3,5-비스(트리플루오로메틸)페닐］메틸］ (2-메틸-2ｈ-테트라졸-5-일)아미노］-2,3,4,5-테트라히드로-7,9-디메틸-1ｈ-1-벤즈아제핀-1-일］메틸］-시클로헥산카르복실산
EP1223170B1 (en) Pyrimidine-5-carboxamide compounds, process for producing the same and use thereof
US20210244729A1 (en) Novel crystalline forms of selinexor and process for their preparation
CN113453760A (zh) Apol1抑制剂及其使用方法
WO2017118277A1 (zh) 一种btk激酶抑制剂的结晶形式及其制备方法
CN104066729A (zh) 溶血磷脂酸受体拮抗剂
CN114031518B (zh) 一种苄胺或苄醇衍生物及其用途
JP6568855B2 (ja) ピラゾール誘導体の製造方法
JP7775186B2 (ja) アクチビン受容体様キナーゼ阻害剤の塩及び結晶形態
US12492213B2 (en) Solid state forms of sep-363856 and process for preparation thereof
JP6816036B2 (ja) ヒストン脱アセチル化阻害剤の結晶形態
AU2017303898A1 (en) Production method for pyrazole-amide compound
AU2019221837B2 (en) Agents and methods for treating dysproliferative diseases
CN111902401B (zh) 受体抑制剂、包含其的药物组合物及其用途
HK1164877A (en) Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid
HK1164877B (en) Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid
TW202415383A (zh) 化合物
CN117945945A (zh) 一种gpr139受体激动剂、其制备方法及其应用

Legal Events

Date Code Title Description
A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20170531

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20170531